Zhengye Biotechnology Holdings/$ZYBT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Zhengye Biotechnology Holdings
Zhengye Biotechnology Holding Ltd is engaged in research, development, manufacturing, and sales of veterinary vaccines, with an emphasis on vaccines for livestock. It has a diverse range of vaccines, including vaccines for swine, cattle, goats, waterfowl, sheep, poultry, and pets, available in various provincial regions across China and are exported overseas to Vietnam, Pakistan, and Egypt. The company generates maximum revenue from the sale of swine vaccines, followed by poultry, and other vaccines.
Ticker
$ZYBT
Sector
Primary listing
Employees
277
Headquarters
Website
ZYBT Metrics
BasicAdvanced
$442M
268.10
$0.03
-
-
Price and volume
Market cap
$442M
52-week high
$14.30
52-week low
$3.50
Average daily volume
219K
Financial strength
Current ratio
1.307
Quick ratio
0.799
Long term debt to equity
1.362
Total debt to equity
24.559
Dividend payout ratio (TTM)
141.66%
Interest coverage (TTM)
4.07%
Profitability
EBITDA (TTM)
5.698
Gross margin (TTM)
48.99%
Net profit margin (TTM)
6.07%
Operating margin (TTM)
8.82%
Effective tax rate (TTM)
6.42%
Revenue per employee (TTM)
$94,030
Management effectiveness
Return on assets (TTM)
2.07%
Return on equity (TTM)
3.89%
Valuation
Price to earnings (TTM)
268.102
Price to revenue (TTM)
16.273
Price to book
1.5
Price to tangible book (TTM)
1.63
Price to free cash flow (TTM)
228.471
Free cash flow yield (TTM)
0.44%
Free cash flow per share (TTM)
0.041
Growth
Revenue change (TTM)
-11.95%
Earnings per share change (TTM)
-64.04%
3-year revenue growth (CAGR)
-4.52%
3-year earnings per share growth (CAGR)
-33.78%
Bulls say / Bears say
The initial public offering closed on January 8, 2025 raised $6.0 million, and the full exercise of the underwriters’ over-allotment option on January 14, 2025 boosted gross proceeds to $6.9 million, providing solid capital for strategic expansion and R&D (SEC Form 6-K, Jan 8, 2025) (SEC Form 6-K, Jan 14, 2025).
The company’s operating entity operates three GMP veterinary vaccine production floors, 13 GMP vaccine production lines, one quality examination center, and one animal facility for vaccine development, highlighting its robust manufacturing infrastructure (SEC Form 6-K Exhibit 99.1, May 23, 2025).
The board appointed Aiden Han as Co-Chief Executive Officer effective March 5, 2025, establishing a clear succession plan and potential for strategic leadership continuity (SEC Form 6-K, Mar 6, 2025).
On May 20, 2025, the company received a NASDAQ delinquency notice for failing to timely file its Form 20-F, risking non-compliance with listing rules and potential delisting (SEC Form 6-K, May 23, 2025).
With an initial public offering of only $6.0 million, Zhengye faces limited liquidity and a thin trading float relative to larger peers, which could hamper market depth and investor interest (SEC Form 6-K, Jan 8, 2025).
The appointment of the chairman’s son, Aiden Han, as Co-CEO raises corporate governance concerns over board independence and nepotism (SEC Form 6-K, Mar 6, 2025).
Data summarised monthly by Lightyear AI. Last updated on 4 Sept 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Zhengye Biotechnology Holdings stock?
Zhengye Biotechnology Holdings (ZYBT) has a market cap of $442M as of September 15, 2025.
What is the P/E ratio for Zhengye Biotechnology Holdings stock?
The price to earnings (P/E) ratio for Zhengye Biotechnology Holdings (ZYBT) stock is 268.1 as of September 15, 2025.
Does Zhengye Biotechnology Holdings stock pay dividends?
No, Zhengye Biotechnology Holdings (ZYBT) stock does not pay dividends to its shareholders as of September 15, 2025.
When is the next Zhengye Biotechnology Holdings dividend payment date?
Zhengye Biotechnology Holdings (ZYBT) stock does not pay dividends to its shareholders.
What is the beta indicator for Zhengye Biotechnology Holdings?
Zhengye Biotechnology Holdings (ZYBT) does not currently have a Beta indicator.